The standard treatment protocol includes target therapy, for example, CDK4 and CDK6 inhibitors, PI3K inhibitors, and anti-PD-L1/PD-1 immunotherapies depending on tumor subtype and molecular environment (8). Here, PIK3CA is linked to neoplasm.